Description

Oxorubdn 10 (Doxorubicin Hydrochloride) 10 mg/vial 

Active ingredient: Doxorubicin Hydrochloride
Dosage form: Lyophilized powder for solution for injection
Strength: 10 mg per vial
Pharmacological group: Antineoplastic agents, anthracyclines
Route of administration: Intravenous
Manufacturer: Biozenta Lifesciences Pvt. Ltd.
Country of origin: India

---

Product Overview

Oxorubdn 10 is a cytotoxic antineoplastic medicinal product containing doxorubicin hydrochloride, a well-established anthracycline chemotherapy agent widely used in modern oncology. The medication is included in numerous standardized chemotherapy protocols and is administered either as part of combination therapy or individualized treatment regimens depending on clinical indication.

Doxorubicin is recognized for its broad antitumor activity and remains a key component in the pharmacological management of multiple malignancies.

---

Mechanism of Action

Doxorubicin exerts its antineoplastic effect through several complementary mechanisms:

• inhibition of DNA and RNA synthesis

• intercalation into DNA strands

• inhibition of topoisomerase II enzyme

• generation of free radicals

• induction of apoptosis in malignant cells

The drug is particularly effective against rapidly dividing tumor cells.

---

Indications

Used under medical supervision for treatment of:

• breast cancer

• soft tissue sarcomas

• osteosarcoma

• lymphomas

• leukemias

• ovarian tumors

• thyroid tumors

• other malignant neoplasms according to clinical protocols

---

Dosage and Administration

The medication is administered intravenously by qualified healthcare professionals only.

Dosage is determined individually based on:

• body surface area

• diagnosis

• stage of disease

• laboratory parameters

• concomitant therapy

⚠ Self-administration is strictly prohibited.

---

Contraindications

• hypersensitivity to doxorubicin or anthracyclines

• severe bone marrow suppression

• severe hepatic impairment

• advanced cardiac insufficiency

• pregnancy and breastfeeding (unless life-saving therapy is required)

---

Adverse Reactions

Possible side effects may include:

• myelosuppression

• nausea and vomiting

• alopecia

• stomatitis

• cardiotoxicity

• elevated liver enzymes

• fatigue and weakness

Regular laboratory monitoring and cardiac evaluation are recommended during therapy.

---

Storage Conditions

Store at temperatures not exceeding 25°C, protected from light, in original packaging.
Do not freeze.
Keep out of reach of children.

---

Special Warnings

Treatment must be performed under supervision of an oncologist. Baseline and periodic evaluation of liver function, cardiac function, and blood parameters is required. This medicine is a potent cytotoxic agent intended for hospital or clinical use only.

---

Conclusion

Oxorubdn 10 is a clinically established antineoplastic chemotherapy agent widely used in oncology protocols. Due to its multi-target mechanism of action, doxorubicin remains an important component of treatment strategies for a variety of malignant diseases.